52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
FDA Says Approves Novartis' Sickle Cell Disease Treatment Adakveo 100 Mg/10 Ml Injection
Novartis Says New Medicine Adakveo® (Crizanlizumab) Approved By FDA
Novartis Gets Positive CHMP Opinion For Mayzent For Treatment Of Adult Patients With Active SPMS
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
Independent Non-Executive Chairman of the Board
Honorary Chairman of the Board
Daniel L. Vasella
Honorary Chairman of the Board
Chief Executive Officer, Member of the Executive Committee
Independent Non-Executive Vice Chairman of the Board
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Swiss-listed eyecare company Alcon reported another quarterly loss, specified its profit outlook, boosted projections for the cost of its spinoff from Novartis and announced a $300 million restructuring program.
Novartis <NOVN.S> is considering an offer for U.S. biotechnology firm The Medicines Co <MDCO.O>, Bloomberg reported on Tuesday, a deal that could broaden the Swiss drugmaker's cabinet of heart medicines and shore up growth threatened by patent expirations.
Swiss drugmaker Novartis on Tuesday declined to comment on a media report that it is considering an offer for U.S. biotechnology company The Medicines Co.
Novartis is exiting drug discovery at its Shanghai site and shifting its focus to drug development, saying accelerating approvals in China are pushing the Swiss company to dedicate the operation's resources to getting its medicines to market.
Novartis is halting early-stage research in Shanghai and shifting the site's focus to commercial development three years after the Swiss drugmaker christened the new $1 billion campus as its Chinese drug discovery hub.
* NOVARTIS PARAGON-HF ANALYSES SUGGEST ENTRESTO® BENEFIT BEYOND HFREF
(The Nov 16 story corrects to clarify in second graph that patients will be infused by a healthcare provider.)
* REG-NEW NOVARTIS MEDICINE ADAKVEO® (CRIZANLIZUMAB) APPROVED BY FDA TO REDUCE FREQUENCY OF PAIN CRISES IN INDIVIDUALS LIVING WITH SICKLE CELL DISEASE
* NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR MAYZENT® (SIPONIMOD) FOR THE TREATMENT OF ADULT PATIENTS WITH ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)
* NEW NOVARTIS PREVENT DATA SHOW COSENTYX DELIVERS EARLY RELIEF IN AXIAL SPONDYLOARTHRITIS
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function in a key study.
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study.
Novartis <NOVN.S> is buying the Japanese generics unit of South Africa's Aspen Pharmacare <APNJ.J> in a deal worth up to 400 million euros ($440.80 million) to expand in the world's third-biggest drug market, the Swiss drugmaker said on Monday.
Aspen Pharmacare Holdings agreed to sell its Japanese operations to Novartis' Sandoz for up to 400 million euros ($440.80 million) through a unit as it looks to cut debt, the South African drugmaker said on Monday.
Novartis' Sandoz generic drug unit is buying Aspen's Japanese operations for an initial payment of 300 million euros ($330.60 million) to expand in the world's third-biggest generic medicines market, the Swiss drugmaker said on Monday.
Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's $4 billion seller Neulasta drug, helping the Swiss drugmaker in its uphill battle to sell copies of rivals' blockbusters in the world's top drug market.
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world's best-selling drug Humira in treating a type of arthritis.
A clinical trial of Novartis's Cosentyx drug has failed to prove it is significantly better than a rival treatment for a type of arthritis, the Swiss company said on Friday.
U.S. regulators have halted a trial of Novartis's Zolgensma treatment after an animal study raised safety concerns, the company said on Wednesday, in a setback for the drugmaker's plan to expand its use to older patients.
* FDA PLACED A PARTIAL HOLD ON AVXS-101 INTRATHECAL CLINICAL TRIALS FOR SMA PATIENTS BASED ON FINDINGS IN A SMALL PRE-CLINICAL ANIMAL STUDY
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.